<DOC>
	<DOCNO>NCT00252668</DOCNO>
	<brief_summary>This study open label extension previously complete double-blind , randomize study compare etanercept methotrexate subject active rheumatoid arthritis . All subject receive combination treatment etanercept methotrexate .</brief_summary>
	<brief_title>Study Evaluating Combination Etanercept Methotrexate Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects complete previous doubleblind , randomize study . Ability reconstitute selfinject test etanercept ( ETN ) designee . Dose prednisone &gt; 10 mg/day ( equivalent ) dose change within 2 week week 0 evaluation . Clinically relevant concurrent medical event include : uncompensated congestive heart failure ( CHF ) , diagnosis multiple sclerosis central demyelinating disease , presence history confirm blood dyscrasia , cancer history cancer , serious infection within 1 month test article administration active infection week 0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>